Jan 21, 2021 · The IsoPSA test is a novel prostate-specific antigen assay for patients with a PSA > 4ng/ml who are facing a decision on prostate biopsy. Listen as Dr. Klein discusses how the IsoPSA test differs from conventional PSA testing and how your patients can benefit.

IsoPSA® - IsoPSA is a structure-based (rather than concentration- based) assay that interrogates the entire spectrum of structural changes to PSA (or isoforms), and can effectively differentiate between high-grade prostate cancer and lowgrade prostate cancer/benign.

IsoPSA is a blood test for men with elevated total PSA ≥ 4ng/mL that identifies structural differences in PSA proteins that are expressed by cancer. IsoPSA can clarify prostate cancer risk, enabling better biopsy decisions for patients who are either biopsy naïve or who have had prior negative biopsy.

May 9, 2022 · The results showed that in men with total PSA ≥4 ng/ml, IsoPSA led to a 55% (284 vs 638) net reduction in prostate biopsy recommendations. Further, there was also a 9% reduction in MRI imaging recommendations.

Dec 14, 2021 · The difference between conventional PSA and the new IsoPSA test has to do with the 3-dimensional molecular form of the PSA protein molecules. A traditional PSA test is a simple count, whereas the IsoPSA can define the distinctive 3-D structure of PSA from the cancer cells.

Jul 7, 2020 · Designed to stratify risk of biologically significant prostate cancer (Gleason grade > 7 prostate cancer), IsoPSA is intended to be used in men who are age 50 and older with a total PSA > 4 ng/ml with no previous prostate cancer diagnosis and not under active surveillance.

Jun 23, 2024 · IsoPSA is a blood test that's indicated for men over 50 years old with a PSA greater than 4 ng/mL. It's meant to be an adjuvant marker for an abnormal PSA. IsoPSA does not simply measure PSA concentration, but it's looking at different isoforms of PSA.

The short answer is that IsoPSA has been shown to be superior to traditional tests, such as PSA, total PSA, and percent free PSA, in predicting high-grade prostate cancer. As such, it has the potential to substantially reduce the number of unnecessary biopsies.

May 20, 2022 · Results of a new study show that IsoPSA, a novel prostate-specific antigen assay, is readily adopted by practitioners in various practice settings, and its use significantly reduces biopsies in men being evaluated for elevated PSA.

Improving cancer decisions - Cleveland Diagnostics offers novel, more accurate testing for early detection of cancer and risk of high-grade disease.